HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xiu-Ju Luo Selected Research

Myosin Light Chains (Myosin Essential Light Chain)

3/2018Fasudil ameliorates the ischemia/reperfusion oxidative injury in rat hearts through suppression of myosin regulatory light chain/NADPH oxidase 2 pathway.
11/2016Phosphorylation of Nonmuscle Myosin Light Chain Promotes Endothelial Injury in Hyperlipidemic Rats Through a Mechanism Involving Downregulation of Dimethylarginine Dimethylaminohydrolase 2.
3/2016Non-muscle myosin light chain promotes endothelial progenitor cells senescence and dysfunction in pulmonary hypertensive rats through up-regulation of NADPH oxidase.
3/2016Involvement of NADPH oxidases and non-muscle myosin light chain in senescence of endothelial progenitor cells in hyperlipidemia.
9/2015Inhibition of myosin light chain kinase reduces NADPH oxidase-mediated oxidative injury in rat brain following cerebral ischemia/reperfusion.
6/2015A novel function of nuclear nonmuscle myosin regulatory light chain in promotion of xanthine oxidase transcription after myocardial ischemia/reperfusion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xiu-Ju Luo Research Topics

Disease

19Ischemia
01/2022 - 03/2012
17Hypoxia (Hypoxemia)
10/2022 - 03/2012
14Infarction (Infarctions)
01/2022 - 05/2012
11Reperfusion Injury
01/2021 - 03/2012
10Necrosis
05/2021 - 11/2016
8Ischemic Stroke
10/2022 - 12/2014
7Brain Injuries (Brain Injury)
10/2022 - 01/2014
7Myocardial Ischemia (Ischemic Heart Diseases)
10/2021 - 03/2012
6Stomach Ulcer (Gastric Ulcer)
11/2016 - 05/2010
5Brain Ischemia (Cerebral Ischemia)
01/2018 - 01/2014
5Hyperlipidemias (Hyperlipidemia)
05/2017 - 11/2015
4Hypertrophy
01/2022 - 06/2014
4Myocardial Infarction
05/2021 - 03/2018
4Inflammation (Inflammations)
06/2020 - 01/2011
4Vascular Remodeling
04/2019 - 06/2014
3Stroke (Strokes)
10/2022 - 01/2016
3Mitochondrial Diseases (Mitochondrial Disease)
05/2020 - 01/2017
3Wounds and Injuries (Trauma)
10/2019 - 03/2018
3Pulmonary Arterial Hypertension
04/2017 - 06/2014
2Cardiovascular Diseases (Cardiovascular Disease)
08/2019 - 01/2015
2Hypertension (High Blood Pressure)
04/2019 - 03/2016
2Pulmonary Hypertension
03/2019 - 06/2014
1Cardiomegaly (Heart Hypertrophy)
01/2022
1Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
01/2022
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2022
1Heart Injuries
05/2021
1Iron Overload
01/2021
1Leukemia
06/2020
1Fibrosis (Cirrhosis)
05/2020
1Macular Degeneration (Age-Related Maculopathy)
01/2020
1Glaucoma
01/2020
1Retinitis Pigmentosa (Pigmentary Retinopathy)
01/2020

Drug/Important Bio-Agent (IBA)

12Proteins (Proteins, Gene)FDA Link
10/2022 - 01/2014
12NADPH Oxidases (NAD(P)H oxidase)IBA
08/2019 - 05/2012
11Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 03/2012
8Creatine Kinase (Creatine Phosphokinase)IBA
05/2021 - 03/2012
8Malondialdehyde (Propanedial)IBA
01/2021 - 08/2011
6Peroxidase (Myeloperoxidase)IBA
10/2021 - 08/2011
6Caspase 3 (Caspase-3)IBA
10/2019 - 09/2011
6Myosin Light Chains (Myosin Essential Light Chain)IBA
03/2018 - 06/2015
6Ethanol (Ethyl Alcohol)IBA
11/2016 - 05/2010
5Phosphotransferases (Kinase)IBA
09/2021 - 01/2018
5Protein Kinases (Protein Kinase)IBA
05/2020 - 01/2018
4Hypochlorous Acid (Hypochlorite)IBA
01/2022 - 11/2015
4Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2022 - 04/2019
4Small Interfering RNA (siRNA)IBA
01/2022 - 01/2018
4Adenosine Triphosphate (ATP)IBA
01/2022 - 10/2019
4lithospermate BIBA
07/2019 - 10/2015
4Biomarkers (Surrogate Marker)IBA
04/2019 - 12/2014
4oxidized low density lipoproteinIBA
01/2018 - 11/2015
4CatalaseIBA
01/2017 - 08/2011
44-hydroxy-2-nonenal (4-hydroxynonenal)IBA
11/2016 - 03/2012
3MicroRNAs (MicroRNA)IBA
01/2022 - 09/2013
3Dynamins (Dynamin)IBA
01/2022 - 01/2019
3Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
08/2019 - 06/2014
33- benzyl- 7- (2- benzoxazolyl)thio- 1,2,3- triazolo(4,5- d)pyrimidineIBA
07/2019 - 10/2015
3erucylphosphocholineIBA
05/2017 - 01/2015
3Myosin-Light-Chain KinaseIBA
09/2015 - 01/2015
3AldehydesIBA
01/2014 - 03/2012
26- hydroxy- 4- (4- hydroxy- 3- methoxyphenyl)- 3- hydroxymethyl- 7- methoxy- 3,4- dihydro- 2- naphthaldehydeIBA
01/2022 - 09/2014
2Xanthine OxidaseIBA
10/2021 - 06/2015
2ponatinibIBA
05/2021 - 01/2018
2Deferoxamine (Desferal)FDA LinkGeneric
05/2021 - 01/2021
2Glutathione PeroxidaseIBA
01/2021 - 08/2011
2IronIBA
01/2021 - 01/2021
2fasudil (AT 877)IBA
03/2018 - 03/2016
2NADPH Oxidase 2IBA
03/2018 - 01/2015
2rho-Associated KinasesIBA
03/2018 - 03/2016
2CateninsIBA
01/2018 - 11/2015
2dimethylargininaseIBA
11/2016 - 05/2010
2Thioctic Acid (Lipoic Acid)IBA
11/2016 - 03/2012
2Glutamic Acid (Glutamate)FDA Link
11/2015 - 12/2014
2NADP (NADPH)IBA
10/2015 - 09/2015
2Messenger RNA (mRNA)IBA
09/2015 - 06/2014
2Superoxide DismutaseIBA
01/2012 - 09/2011
1Polymyxin B (Aerosporin)FDA LinkGeneric
10/2022
1Endosomal Sorting Complexes Required for TransportIBA
10/2022
12- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA
01/2022
1sodium bisulfide (NaHS)IBA
01/2022
1dipsacoside BIBA
01/2022
1Uric Acid (Urate)IBA
10/2021
1Allopurinol (Remid)FDA LinkGeneric
10/2021
1Caspofungin (Cancidas)FDA Link
09/2021
1Glucose (Dextrose)FDA LinkGeneric
09/2021
1Oxygen (Dioxygen)IBA
09/2021
1Cyclophilins (Cyclophilin)IBA
05/2021
1Cyclosporine (Ciclosporin)FDA LinkGeneric
05/2021
1Chelating AgentsIBA
01/2021
1Transferrin Receptors (Transferrin Receptor)IBA
01/2021
1Ubiquitin-Specific ProteasesIBA
01/2021
1jujuboside BIBA
06/2020
1jujube extractIBA
06/2020
1SaponinsIBA
06/2020
1arctiinIBA
05/2020
1Mitochondrial Proteins (Mitochondrial Protein)IBA
05/2020
1UbiquitinIBA
05/2020
1Retinal Pigments (Pigments, Visual)IBA
01/2020
1Cytochromes c (Cytochrome c)IBA
10/2019

Therapy/Procedure

3Oral Administration
09/2013 - 08/2011
2Therapeutics
05/2021 - 01/2021